- Yissum - Research Development Company of the Hebrew University
- From Israel
- Innovative Products and Technologies
Summary of the technology
Novel synergic drug-combination for improved activation of the human opioid receptor (MOR), with expected avoidance of drug-addiction, using lower effective clinical doses
Avoiding Drug Addiction Using a Novel Drug Combination for Improved Activation of the Opioid Receptor
Project ID : 6-2018-5679
Details of the Technology Offer
LifeSciences and BioTechnology
Pain, Opioid receptor, Addiction, Opioid addiction, Narcotics, Analgesia
Severe, high-impact chronic pain affects 20 million people in the US annually, and presents a common, difficult-to-treat clinical challenge. All the drugs currently approved for chronic treatment of severe pain are narcotics, and their main mechanism of action is activation of the mu-opioid receptor (MOR) in the CNS. Long-term narcotic use is associated with dependence and addiction, with the risk of death by overdose, and with other severe adverse effects. In the US, an estimated 2 million individuals suffer from opioid addiction associated with prescription opioids, accounting for an estimated $78.5 billion in economic costs annually. The estimated overall annual cost of chronic pain in the US is $560 billion in direct medical costs, lost productivity, and disability programs. Thus, there is an urgent and widespread need for safer, non-narcotic drugs that will provide strong and chronic pain relief without the adverse effects associated with narcotic use.
We have identified a combination of two approved, non-narcotic drugs (Drug A and Drug B) that together are capable of activating MOR synergistically, at very low doses of either drug: Drug A at < 10% of its usually-prescribed dose, and Drug B at < 5% of its usually-prescribed dose.
To test the synergy between Drugs A & B, we utilized a cell-based assay system in which the human mu-opioid receptor (h-MOR) is expressed exclusively. In addition, the system includes h MOR’s downstream cAMP signaling pathway, and a sensitive means to measure Gi’s inhibitory effect on adenylyl cyclase activity following Gi’s activation by h-MOR.
A dose-response test was performed for each drug separately, and for various combinations of Drug A and Drug B. We found that at concentrations in which Drug A and Drug B by themselves only produced negligible responses, their combination yielded robust adenylyl cyclase inhibition of more than 5 times that of the individual drugs.
Moreover, this synergic effect extended through a range close to two orders of magnitude of drug concentrations for either drug, at pharmacologically-relevant concentrations.
This is a novel combination of two non-opioid, clinically-approved drugs that together achieve a synergistic activation of MOR in very low doses of either drug. This combination, with a possible 505b2 route of approval, offers narcotic-strength analgesia without the dangerous adverse effects associated with chronic narcotic use.